Fischer Laurent 4

What Happened

• Laurent Fischer, a director of Mirum Pharmaceuticals (MIRM), was granted two derivative awards on 2026-06-15 totaling 5,752 shares: 3,772 derivative shares (option-like award) and 1,980 deferred stock units. Both grants show $0.00 paid at grant (i.e., no cash outlay) and are reported as awards rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-06-15; Form 4 filed 2026-06-17 (timely).
• Grant details: 3,772 derivative shares @ $0.00 (see footnote F1); 1,980 deferred stock units @ $0.00 (see footnote F2).
• Total awarded: 5,752 derivative share equivalents; no purchase price or cash exchanged at grant.
• Shares owned after transaction: not specified in the excerpt provided.
• Footnote highlights:
  • F1: The 3,772 award vests on the first anniversary of the grant date, and in any event will be fully vested by the issuer’s 2027 annual stockholder meeting (described as option-like vesting).
  • F2: Each deferred stock unit represents a contingent right to one share, vests on the first anniversary (or by the 2027 annual meeting), and will be paid in common stock upon a change in control or within 60 days after separation from service.
• Filing timeliness: Filed within two business days of the transaction date (no late filing flag).

Context

• These are compensation awards (an option-style grant and deferred stock units). They are not open‑market purchases or sales and therefore do not directly signal buying or selling sentiment.
• Deferred stock units convert to shares only upon vesting and specified payout events; the option-like award will vest over time (or by the 2027 meeting). Retail investors should view these as part of director compensation rather than immediate stock accumulation for trading purposes.